Sulodexide solution

Sulodexide solution is a mixture of glycosaminoglycans that can be administered by injection. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease. In Vitro: Sulodexide (0–200 μg/mL, 24 hours) promotes fibronectin and collagen type III synthesis in mouse mesangial cells^[2].
Sulodexide (50 µg/mL, 48 hours) significantly inhibits capillarization marker expression in LSECs^[4].
In Vivo: Sulodexide (5 mg/kg and 15 mg/kg, i.p., once daily for 5 days) significantly inhibits retinal neovascularization and suppressed pro-angiogenic protein expression in the oxygen-induced retinopathy model in ICR mice^[3].